Replies to post #147075 on Biotech Values

[pcrutch]

Thanks for the notes as usual

4. ARRY expects AZN to report P2 selumetinib+DTIC data in BRAF melanoma patients at an upcoming scientific meeting.

Sounds like ESMO in Sept or EORTC-NCI-AACR in Nov?

[turtlepower]

ARRY - I gather that one reason for the positive reaction could be that the PR states that there could be a P3 for selumetinib completed by 2013. That's intriguing if I understood it correctly. Sounds like a small trial powered for PFS if true. Do you recall this being addressed during the CC?

[NP1986]

Koch claims the sustained decrease in blood pressure with 797 treatment may actually be beneficial to the drug's profile. In pre-clinical animal models, ARRY has increased OS in CHF animal models with 797.

Koch also mentioned that GSK has a p38 inhibitor in a trial for ACS. I believe this is the one:
http://www.clinicaltrials.gov/ct2/show/NCT00910962?term=p38&recr=Open&rank=11